Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (171-180 of 273) with videos related to

Pageof 28
Sort By:
Plos One|September 29, 2015
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR ApproachAlexandra Pender, Isaac Garcia-Murillas, Sareena Rana, et al.
Oncotargets and Therapy|August 29, 2022
Sequential Afatinib and Osimertinib in Asian Patients with <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional StudiesSatoru Miura, Hyun Ae Jung, Shin Yup Lee, et al.
Journal of Clinical Medicine|January 8, 2023
Mobocertinib (TAK-788) in <i>EGFR</i> Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension CohortMaria Rosario Garcia Campelo, Caicun Zhou, Suresh S Ramalingam, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2013
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)Mary E R O'Brien, Rabab M Gaafar, Sanjay Popat, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)Mary E R O'Brien, Rabab Gaafar, Baktiar Hasan, et al.
The Lancet Regional Health. Europe|March 13, 2024
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across EuropeIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
Thorax|October 14, 2010
Guidelines on the radical management of patients with lung cancerEric Lim, David Baldwin, Michael Beckles, et al.
Lung Cancer (Amsterdam, Netherlands)|October 14, 2021
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, et al.
The Lancet. Oncology|September 19, 2014
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient dataAntonio Rossi, Paolo Chiodini, Jong-Mu Sun, et al.
BJC Reports|November 8, 2024
Incidental finding of leukaemia in circulating tumour DNA- the importance of a molecular tumour boardJustin Mencel, Neha Rayarel, Paula Proszek, et al.
Pageof 28

Showing results (171-180 of 273) with videos related to

Sort By:
Pageof 28
Plos One|September 29, 2015
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR ApproachAlexandra Pender, Isaac Garcia-Murillas, Sareena Rana, et al.
Oncotargets and Therapy|August 29, 2022
Sequential Afatinib and Osimertinib in Asian Patients with <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional StudiesSatoru Miura, Hyun Ae Jung, Shin Yup Lee, et al.
Journal of Clinical Medicine|January 8, 2023
Mobocertinib (TAK-788) in <i>EGFR</i> Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension CohortMaria Rosario Garcia Campelo, Caicun Zhou, Suresh S Ramalingam, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2013
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)Mary E R O'Brien, Rabab M Gaafar, Sanjay Popat, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)Mary E R O'Brien, Rabab Gaafar, Baktiar Hasan, et al.
The Lancet Regional Health. Europe|March 13, 2024
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across EuropeIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
Thorax|October 14, 2010
Guidelines on the radical management of patients with lung cancerEric Lim, David Baldwin, Michael Beckles, et al.
Lung Cancer (Amsterdam, Netherlands)|October 14, 2021
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, et al.
The Lancet. Oncology|September 19, 2014
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient dataAntonio Rossi, Paolo Chiodini, Jong-Mu Sun, et al.
BJC Reports|November 8, 2024
Incidental finding of leukaemia in circulating tumour DNA- the importance of a molecular tumour boardJustin Mencel, Neha Rayarel, Paula Proszek, et al.
Pageof 28